Merck to Suspend Availability of TREDAPTIVE Worldwide
Merck (NYSE: MRK), known as MSD outside of the United States and Canada,
today announced the company is taking steps to suspend the availability
of TREDAPTIVE™ (extended-release niacin/laropiprant) tablets
worldwide. TREDAPTIVE is not approved for use in the United States.
Merck is taking these steps based on the current understanding of the
preliminary data from the HPS2-THRIVE (Heart Protection Study
2-Treatment of HDL to Reduce the Incidence
of Vascular Events) study, and in consultation with
regulatory authorities. As previously reported by Merck (Dec.
20, 2012 news release), HPS2-THRIVE did not achieve its primary
endpoint of reduction of major vascular events, and there was a
statistically significant increase in the incidence of some types of